Syn 1002

Drug Profile

Syn 1002

Alternative Names: PAT; Peptide analogue of thymulin; SYN 1002; Syn1002

Latest Information Update: 31 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator INSERM
  • Developer CLL PHARMA
  • Class Analgesics; Anti-inflammatories; Antirheumatics; Oligopeptides
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Crohn's disease; Pain
  • No development reported Neuropathic pain; Rheumatoid arthritis

Most Recent Events

  • 31 May 2016 Phase-I development is ongoing for Pain and Crohn's disease in France (CII PHARMA pipeline, May 2016)
  • 19 May 2016 No recent reports on development identified - Phase-I for Neuropathic pain and Rheumatoid arthritis in France (unspecified route)
  • 25 Jun 2004 Preclinical trials in Neuropathic pain in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top